Department of Community Medicine, Faculty of Medicine, Social Determinants of Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Medical Doctor Ramsar Campus, Mazandaran University of Medical Sciences, Ramsar, Iran.
Curr Microbiol. 2024 Aug 24;81(10):326. doi: 10.1007/s00284-024-03853-z.
Even though the number of effective anti-tuberculosis or anti-mycobacterial agents is increasing, a large number of patients experience severe side effects as a result of these drugs. This hurts the patients' well-being and quality of life. Tumor cells that survive treatment modalities can become chemotherapy resistant at the molecular level. Furthermore, negative effects on normal cells occur concurrently. Strategies that minimize the negative effects on normal cells while efficiently targeting infected cells are required. Nanotherapies, according to recent research, may be one option in this direction. The present study differs from previously published review studies as it concentrates on examining the most recently developed nanoparticles for anti-mycobacterial purposes. Such novel approaches have the potential to reduce harmful side effects and improve patients' health prognoses. Current paper provides a comprehensive analysis of recent advances in nanotherapy systems for the pulmonary delivery of anti-tuberculous drugs. In addition, to low-priced and convenient alternatives for pulmonary delivery, different types of NPs for oral and topical application were also deliberated and summarized in this review.
尽管有效的抗结核或抗分枝杆菌药物的数量在增加,但大量患者因这些药物而出现严重的副作用。这会损害患者的健康和生活质量。在分子水平上,治疗后存活下来的肿瘤细胞可能会对化疗产生耐药性。此外,正常细胞也会同时受到负面影响。需要寻找一种既能最大限度地减少对正常细胞的负面影响,又能有效地靶向感染细胞的策略。最近的研究表明,纳米疗法可能是一种选择。本研究与之前发表的综述研究不同,它专注于检查最近为抗分枝杆菌目的而开发的新型纳米颗粒。这些新方法有可能减少有害的副作用,并改善患者的健康预后。本文对用于肺部递抗结核药物的纳米治疗系统的最新进展进行了全面分析。此外,为了寻找更廉价、更方便的肺部递药替代方法,本文还对口服和局部应用的不同类型 NPs 进行了审议和总结。